nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.326	0.708	CbGbCtD
Pazopanib—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.135	0.292	CbGbCtD
Pazopanib—Peritonitis—Riluzole—amyotrophic lateral sclerosis	0.00949	0.0541	CcSEcCtD
Pazopanib—FGFR3—appendage—amyotrophic lateral sclerosis	0.00591	0.0362	CbGeAlD
Pazopanib—BMPR1B—peripheral nervous system—amyotrophic lateral sclerosis	0.00532	0.0326	CbGeAlD
Pazopanib—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00482	0.0275	CcSEcCtD
Pazopanib—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.00482	0.0275	CcSEcCtD
Pazopanib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00469	0.0267	CcSEcCtD
Pazopanib—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00433	0.0247	CcSEcCtD
Pazopanib—FGF1—appendage—amyotrophic lateral sclerosis	0.0041	0.0251	CbGeAlD
Pazopanib—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00403	0.023	CcSEcCtD
Pazopanib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00394	0.0225	CcSEcCtD
Pazopanib—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00374	0.0213	CcSEcCtD
Pazopanib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00359	0.0204	CcSEcCtD
Pazopanib—KDR—hindlimb—amyotrophic lateral sclerosis	0.00353	0.0217	CbGeAlD
Pazopanib—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00345	0.0197	CcSEcCtD
Pazopanib—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00339	0.0193	CcSEcCtD
Pazopanib—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00336	0.0191	CcSEcCtD
Pazopanib—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00324	0.0185	CcSEcCtD
Pazopanib—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00308	0.0176	CcSEcCtD
Pazopanib—KDR—appendage—amyotrophic lateral sclerosis	0.00303	0.0186	CbGeAlD
Pazopanib—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00298	0.017	CcSEcCtD
Pazopanib—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00296	0.0169	CcSEcCtD
Pazopanib—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00292	0.0166	CcSEcCtD
Pazopanib—FGF1—nerve—amyotrophic lateral sclerosis	0.0029	0.0178	CbGeAlD
Pazopanib—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00289	0.0165	CcSEcCtD
Pazopanib—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00254	0.0145	CcSEcCtD
Pazopanib—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.0024	0.0137	CcSEcCtD
Pazopanib—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.0024	0.0137	CcSEcCtD
Pazopanib—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.0024	0.0137	CcSEcCtD
Pazopanib—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00234	0.0134	CcSEcCtD
Pazopanib—FGF1—hindbrain—amyotrophic lateral sclerosis	0.00217	0.0133	CbGeAlD
Pazopanib—FGFR2—hindbrain—amyotrophic lateral sclerosis	0.00205	0.0126	CbGeAlD
Pazopanib—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.002	0.0114	CcSEcCtD
Pazopanib—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0114	CcSEcCtD
Pazopanib—FGFR3—embryo—amyotrophic lateral sclerosis	0.00196	0.012	CbGeAlD
Pazopanib—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00192	0.0109	CcSEcCtD
Pazopanib—TAOK3—hindbrain—amyotrophic lateral sclerosis	0.0018	0.011	CbGeAlD
Pazopanib—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00178	0.0102	CcSEcCtD
Pazopanib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00996	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00992	CcSEcCtD
Pazopanib—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00958	CcSEcCtD
Pazopanib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00923	CcSEcCtD
Pazopanib—MAP2K5—hindbrain—amyotrophic lateral sclerosis	0.00161	0.00987	CbGeAlD
Pazopanib—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00916	CcSEcCtD
Pazopanib—MAP3K9—nervous system—amyotrophic lateral sclerosis	0.00159	0.00977	CbGeAlD
Pazopanib—TAOK1—medulla oblongata—amyotrophic lateral sclerosis	0.00159	0.00976	CbGeAlD
Pazopanib—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00897	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00893	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00875	CcSEcCtD
Pazopanib—MAP3K9—central nervous system—amyotrophic lateral sclerosis	0.00153	0.0094	CbGeAlD
Pazopanib—FLT4—embryo—amyotrophic lateral sclerosis	0.00153	0.00939	CbGeAlD
Pazopanib—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00863	CcSEcCtD
Pazopanib—MAP3K9—cerebellum—amyotrophic lateral sclerosis	0.0015	0.00919	CbGeAlD
Pazopanib—SH2B3—medulla oblongata—amyotrophic lateral sclerosis	0.0015	0.00919	CbGeAlD
Pazopanib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00841	CcSEcCtD
Pazopanib—KIT—hindbrain—amyotrophic lateral sclerosis	0.00143	0.00875	CbGeAlD
Pazopanib—TAOK1—spinal cord—amyotrophic lateral sclerosis	0.00142	0.0087	CbGeAlD
Pazopanib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00802	CcSEcCtD
Pazopanib—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00783	CcSEcCtD
Pazopanib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00776	CcSEcCtD
Pazopanib—FGF1—embryo—amyotrophic lateral sclerosis	0.00136	0.00834	CbGeAlD
Pazopanib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00765	CcSEcCtD
Pazopanib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00765	CcSEcCtD
Pazopanib—SH2B3—spinal cord—amyotrophic lateral sclerosis	0.00134	0.00819	CbGeAlD
Pazopanib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00754	CcSEcCtD
Pazopanib—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00749	CcSEcCtD
Pazopanib—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00745	CcSEcCtD
Pazopanib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00745	CcSEcCtD
Pazopanib—FGFR2—embryo—amyotrophic lateral sclerosis	0.00128	0.00788	CbGeAlD
Pazopanib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00729	CcSEcCtD
Pazopanib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00723	CcSEcCtD
Pazopanib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00721	CcSEcCtD
Pazopanib—RIOK2—medulla oblongata—amyotrophic lateral sclerosis	0.00125	0.00769	CbGeAlD
Pazopanib—FGFR3—medulla oblongata—amyotrophic lateral sclerosis	0.00125	0.00769	CbGeAlD
Pazopanib—FGF1—brainstem—amyotrophic lateral sclerosis	0.00125	0.00764	CbGeAlD
Pazopanib—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00699	CcSEcCtD
Pazopanib—MAP3K9—brain—amyotrophic lateral sclerosis	0.00122	0.00747	CbGeAlD
Pazopanib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00121	0.0069	CcSEcCtD
Pazopanib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00686	CcSEcCtD
Pazopanib—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00683	CcSEcCtD
Pazopanib—TAOK1—nervous system—amyotrophic lateral sclerosis	0.0012	0.00733	CbGeAlD
Pazopanib—FLT1—embryo—amyotrophic lateral sclerosis	0.00119	0.0073	CbGeAlD
Pazopanib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00678	CcSEcCtD
Pazopanib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00676	CcSEcCtD
Pazopanib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00674	CcSEcCtD
Pazopanib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00673	CcSEcCtD
Pazopanib—FGFR2—brainstem—amyotrophic lateral sclerosis	0.00118	0.00722	CbGeAlD
Pazopanib—TAOK1—central nervous system—amyotrophic lateral sclerosis	0.00115	0.00706	CbGeAlD
Pazopanib—STK36—medulla oblongata—amyotrophic lateral sclerosis	0.00113	0.00691	CbGeAlD
Pazopanib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00641	CcSEcCtD
Pazopanib—SH2B3—nervous system—amyotrophic lateral sclerosis	0.00113	0.0069	CbGeAlD
Pazopanib—TAOK1—cerebellum—amyotrophic lateral sclerosis	0.00113	0.0069	CbGeAlD
Pazopanib—FGFR3—spinal cord—amyotrophic lateral sclerosis	0.00112	0.00686	CbGeAlD
Pazopanib—RIOK2—spinal cord—amyotrophic lateral sclerosis	0.00112	0.00686	CbGeAlD
Pazopanib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00637	CcSEcCtD
Pazopanib—PDGFRA—embryo—amyotrophic lateral sclerosis	0.00112	0.00684	CbGeAlD
Pazopanib—PI4KB—medulla oblongata—amyotrophic lateral sclerosis	0.00111	0.0068	CbGeAlD
Pazopanib—AURKC—nervous system—amyotrophic lateral sclerosis	0.00111	0.0068	CbGeAlD
Pazopanib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00623	CcSEcCtD
Pazopanib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00619	CcSEcCtD
Pazopanib—SH2B3—central nervous system—amyotrophic lateral sclerosis	0.00108	0.00665	CbGeAlD
Pazopanib—Chills—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00616	CcSEcCtD
Pazopanib—AURKC—central nervous system—amyotrophic lateral sclerosis	0.00107	0.00654	CbGeAlD
Pazopanib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00607	CcSEcCtD
Pazopanib—SH2B3—cerebellum—amyotrophic lateral sclerosis	0.00106	0.0065	CbGeAlD
Pazopanib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00601	CcSEcCtD
Pazopanib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00597	CcSEcCtD
Pazopanib—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00589	CcSEcCtD
Pazopanib—TAOK3—brainstem—amyotrophic lateral sclerosis	0.00103	0.00631	CbGeAlD
Pazopanib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00585	CcSEcCtD
Pazopanib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00574	CcSEcCtD
Pazopanib—KDR—embryo—amyotrophic lateral sclerosis	0.00101	0.00617	CbGeAlD
Pazopanib—PI4KB—spinal cord—amyotrophic lateral sclerosis	0.000989	0.00607	CbGeAlD
Pazopanib—CSF1R—embryo—amyotrophic lateral sclerosis	0.000982	0.00602	CbGeAlD
Pazopanib—PIP4K2C—medulla oblongata—amyotrophic lateral sclerosis	0.000973	0.00597	CbGeAlD
Pazopanib—LIMK2—spinal cord—amyotrophic lateral sclerosis	0.000971	0.00596	CbGeAlD
Pazopanib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000969	0.00552	CcSEcCtD
Pazopanib—FGFR1—medulla oblongata—amyotrophic lateral sclerosis	0.000965	0.00592	CbGeAlD
Pazopanib—STK16—nervous system—amyotrophic lateral sclerosis	0.000957	0.00587	CbGeAlD
Pazopanib—LYN—nervous system—amyotrophic lateral sclerosis	0.000947	0.00581	CbGeAlD
Pazopanib—RIOK2—nervous system—amyotrophic lateral sclerosis	0.000942	0.00578	CbGeAlD
Pazopanib—FGFR3—nervous system—amyotrophic lateral sclerosis	0.000942	0.00578	CbGeAlD
Pazopanib—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00094	0.00536	CcSEcCtD
Pazopanib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000939	0.00535	CcSEcCtD
Pazopanib—MAP3K19—nervous system—amyotrophic lateral sclerosis	0.000933	0.00572	CbGeAlD
Pazopanib—BMPR1B—nervous system—amyotrophic lateral sclerosis	0.000933	0.00572	CbGeAlD
Pazopanib—MAP2K5—brainstem—amyotrophic lateral sclerosis	0.000922	0.00566	CbGeAlD
Pazopanib—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000922	0.00525	CcSEcCtD
Pazopanib—STK16—central nervous system—amyotrophic lateral sclerosis	0.000921	0.00565	CbGeAlD
Pazopanib—Cough—Riluzole—amyotrophic lateral sclerosis	0.000915	0.00521	CcSEcCtD
Pazopanib—TAOK1—brain—amyotrophic lateral sclerosis	0.000914	0.0056	CbGeAlD
Pazopanib—LYN—central nervous system—amyotrophic lateral sclerosis	0.000912	0.00559	CbGeAlD
Pazopanib—RIOK2—central nervous system—amyotrophic lateral sclerosis	0.000907	0.00556	CbGeAlD
Pazopanib—FGFR3—central nervous system—amyotrophic lateral sclerosis	0.000907	0.00556	CbGeAlD
Pazopanib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000905	0.00516	CcSEcCtD
Pazopanib—STK16—cerebellum—amyotrophic lateral sclerosis	0.000901	0.00552	CbGeAlD
Pazopanib—MAP3K19—central nervous system—amyotrophic lateral sclerosis	0.000898	0.00551	CbGeAlD
Pazopanib—BMPR1B—central nervous system—amyotrophic lateral sclerosis	0.000898	0.00551	CbGeAlD
Pazopanib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000893	0.00509	CcSEcCtD
Pazopanib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000893	0.00509	CcSEcCtD
Pazopanib—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000893	0.00509	CcSEcCtD
Pazopanib—KIT—embryo—amyotrophic lateral sclerosis	0.000892	0.00547	CbGeAlD
Pazopanib—RIOK2—cerebellum—amyotrophic lateral sclerosis	0.000887	0.00544	CbGeAlD
Pazopanib—FGFR3—cerebellum—amyotrophic lateral sclerosis	0.000887	0.00544	CbGeAlD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000886	0.00505	CcSEcCtD
Pazopanib—BMPR1B—cerebellum—amyotrophic lateral sclerosis	0.000878	0.00538	CbGeAlD
Pazopanib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000873	0.00497	CcSEcCtD
Pazopanib—PDGFRB—embryo—amyotrophic lateral sclerosis	0.000871	0.00534	CbGeAlD
Pazopanib—FGF1—medulla oblongata—amyotrophic lateral sclerosis	0.000869	0.00533	CbGeAlD
Pazopanib—PIP4K2C—spinal cord—amyotrophic lateral sclerosis	0.000868	0.00532	CbGeAlD
Pazopanib—FGFR1—spinal cord—amyotrophic lateral sclerosis	0.000861	0.00528	CbGeAlD
Pazopanib—SH2B3—brain—amyotrophic lateral sclerosis	0.00086	0.00528	CbGeAlD
Pazopanib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000856	0.00488	CcSEcCtD
Pazopanib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00085	0.00484	CcSEcCtD
Pazopanib—AURKC—brain—amyotrophic lateral sclerosis	0.000847	0.00519	CbGeAlD
Pazopanib—STK36—nervous system—amyotrophic lateral sclerosis	0.000846	0.00519	CbGeAlD
Pazopanib—Shock—Riluzole—amyotrophic lateral sclerosis	0.000842	0.0048	CcSEcCtD
Pazopanib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000839	0.00478	CcSEcCtD
Pazopanib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000838	0.00477	CcSEcCtD
Pazopanib—PI4KB—nervous system—amyotrophic lateral sclerosis	0.000833	0.00511	CbGeAlD
Pazopanib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000831	0.00474	CcSEcCtD
Pazopanib—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000827	0.00471	CcSEcCtD
Pazopanib—LIMK2—nervous system—amyotrophic lateral sclerosis	0.000818	0.00502	CbGeAlD
Pazopanib—KIT—brainstem—amyotrophic lateral sclerosis	0.000817	0.00501	CbGeAlD
Pazopanib—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000816	0.00465	CcSEcCtD
Pazopanib—STK36—central nervous system—amyotrophic lateral sclerosis	0.000815	0.005	CbGeAlD
Pazopanib—PI4KB—central nervous system—amyotrophic lateral sclerosis	0.000802	0.00492	CbGeAlD
Pazopanib—STK36—cerebellum—amyotrophic lateral sclerosis	0.000796	0.00488	CbGeAlD
Pazopanib—LIMK2—central nervous system—amyotrophic lateral sclerosis	0.000788	0.00483	CbGeAlD
Pazopanib—PI4KB—cerebellum—amyotrophic lateral sclerosis	0.000784	0.00481	CbGeAlD
Pazopanib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00444	CcSEcCtD
Pazopanib—FGF1—spinal cord—amyotrophic lateral sclerosis	0.000775	0.00475	CbGeAlD
Pazopanib—PLK4—brain—amyotrophic lateral sclerosis	0.000775	0.00475	CbGeAlD
Pazopanib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000774	0.00441	CcSEcCtD
Pazopanib—LIMK2—cerebellum—amyotrophic lateral sclerosis	0.00077	0.00472	CbGeAlD
Pazopanib—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000768	0.00438	CcSEcCtD
Pazopanib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000763	0.00435	CcSEcCtD
Pazopanib—FLT1—medulla oblongata—amyotrophic lateral sclerosis	0.000761	0.00467	CbGeAlD
Pazopanib—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000761	0.00434	CcSEcCtD
Pazopanib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000753	0.00429	CcSEcCtD
Pazopanib—EPHB6—medulla oblongata—amyotrophic lateral sclerosis	0.000752	0.00461	CbGeAlD
Pazopanib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000744	0.00424	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000739	0.00421	CcSEcCtD
Pazopanib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000738	0.0042	CcSEcCtD
Pazopanib—FGFR2—spinal cord—amyotrophic lateral sclerosis	0.000732	0.00449	CbGeAlD
Pazopanib—Pain—Riluzole—amyotrophic lateral sclerosis	0.000732	0.00417	CcSEcCtD
Pazopanib—STK16—brain—amyotrophic lateral sclerosis	0.000731	0.00449	CbGeAlD
Pazopanib—PIP4K2C—nervous system—amyotrophic lateral sclerosis	0.000731	0.00448	CbGeAlD
Pazopanib—LYN—brain—amyotrophic lateral sclerosis	0.000724	0.00444	CbGeAlD
Pazopanib—FGFR3—brain—amyotrophic lateral sclerosis	0.00072	0.00442	CbGeAlD
Pazopanib—RIOK2—brain—amyotrophic lateral sclerosis	0.00072	0.00442	CbGeAlD
Pazopanib—TAOK3—medulla oblongata—amyotrophic lateral sclerosis	0.000717	0.0044	CbGeAlD
Pazopanib—MAP3K19—brain—amyotrophic lateral sclerosis	0.000713	0.00437	CbGeAlD
Pazopanib—BMPR1B—brain—amyotrophic lateral sclerosis	0.000713	0.00437	CbGeAlD
Pazopanib—PIP4K2C—central nervous system—amyotrophic lateral sclerosis	0.000704	0.00432	CbGeAlD
Pazopanib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00399	CcSEcCtD
Pazopanib—MAP3K2—nervous system—amyotrophic lateral sclerosis	0.000693	0.00425	CbGeAlD
Pazopanib—PIP4K2C—cerebellum—amyotrophic lateral sclerosis	0.000688	0.00422	CbGeAlD
Pazopanib—FGFR1—cerebellum—amyotrophic lateral sclerosis	0.000683	0.00419	CbGeAlD
Pazopanib—FLT1—spinal cord—amyotrophic lateral sclerosis	0.000678	0.00416	CbGeAlD
Pazopanib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000676	0.00385	CcSEcCtD
Pazopanib—EPHB6—spinal cord—amyotrophic lateral sclerosis	0.000671	0.00411	CbGeAlD
Pazopanib—MAP3K2—central nervous system—amyotrophic lateral sclerosis	0.000667	0.00409	CbGeAlD
Pazopanib—FGF1—nervous system—amyotrophic lateral sclerosis	0.000653	0.00401	CbGeAlD
Pazopanib—MAP3K2—cerebellum—amyotrophic lateral sclerosis	0.000652	0.004	CbGeAlD
Pazopanib—STK36—brain—amyotrophic lateral sclerosis	0.000647	0.00397	CbGeAlD
Pazopanib—KDR—medulla oblongata—amyotrophic lateral sclerosis	0.000643	0.00394	CbGeAlD
Pazopanib—MAP2K5—medulla oblongata—amyotrophic lateral sclerosis	0.000643	0.00394	CbGeAlD
Pazopanib—TAOK3—spinal cord—amyotrophic lateral sclerosis	0.00064	0.00392	CbGeAlD
Pazopanib—PI4KB—brain—amyotrophic lateral sclerosis	0.000637	0.00391	CbGeAlD
Pazopanib—PDGFRA—spinal cord—amyotrophic lateral sclerosis	0.000636	0.0039	CbGeAlD
Pazopanib—FGF1—central nervous system—amyotrophic lateral sclerosis	0.000629	0.00386	CbGeAlD
Pazopanib—CSF1R—medulla oblongata—amyotrophic lateral sclerosis	0.000628	0.00385	CbGeAlD
Pazopanib—LIMK2—brain—amyotrophic lateral sclerosis	0.000625	0.00384	CbGeAlD
Pazopanib—FGFR2—nervous system—amyotrophic lateral sclerosis	0.000617	0.00378	CbGeAlD
Pazopanib—FGF1—cerebellum—amyotrophic lateral sclerosis	0.000615	0.00377	CbGeAlD
Pazopanib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000614	0.0035	CcSEcCtD
Pazopanib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000605	0.00345	CcSEcCtD
Pazopanib—FGFR2—central nervous system—amyotrophic lateral sclerosis	0.000594	0.00364	CbGeAlD
Pazopanib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000585	0.00334	CcSEcCtD
Pazopanib—FGFR2—cerebellum—amyotrophic lateral sclerosis	0.00058	0.00356	CbGeAlD
Pazopanib—KDR—spinal cord—amyotrophic lateral sclerosis	0.000573	0.00352	CbGeAlD
Pazopanib—MAP2K5—spinal cord—amyotrophic lateral sclerosis	0.000573	0.00352	CbGeAlD
Pazopanib—FLT1—nervous system—amyotrophic lateral sclerosis	0.000572	0.00351	CbGeAlD
Pazopanib—KIT—medulla oblongata—amyotrophic lateral sclerosis	0.00057	0.0035	CbGeAlD
Pazopanib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000566	0.00322	CcSEcCtD
Pazopanib—EPHB6—nervous system—amyotrophic lateral sclerosis	0.000565	0.00347	CbGeAlD
Pazopanib—FLT4—brain—amyotrophic lateral sclerosis	0.000562	0.00345	CbGeAlD
Pazopanib—CSF1R—spinal cord—amyotrophic lateral sclerosis	0.00056	0.00343	CbGeAlD
Pazopanib—PIP4K2C—brain—amyotrophic lateral sclerosis	0.000559	0.00343	CbGeAlD
Pazopanib—PDGFRB—medulla oblongata—amyotrophic lateral sclerosis	0.000557	0.00341	CbGeAlD
Pazopanib—FGFR1—brain—amyotrophic lateral sclerosis	0.000554	0.0034	CbGeAlD
Pazopanib—FLT1—central nervous system—amyotrophic lateral sclerosis	0.00055	0.00338	CbGeAlD
Pazopanib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000544	0.0031	CcSEcCtD
Pazopanib—EPHB6—central nervous system—amyotrophic lateral sclerosis	0.000544	0.00334	CbGeAlD
Pazopanib—STK10—nervous system—amyotrophic lateral sclerosis	0.000541	0.00332	CbGeAlD
Pazopanib—Rash—Riluzole—amyotrophic lateral sclerosis	0.00054	0.00307	CcSEcCtD
Pazopanib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000539	0.00307	CcSEcCtD
Pazopanib—TAOK3—nervous system—amyotrophic lateral sclerosis	0.000539	0.00331	CbGeAlD
Pazopanib—FLT1—cerebellum—amyotrophic lateral sclerosis	0.000538	0.0033	CbGeAlD
Pazopanib—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000537	0.00329	CbGeAlD
Pazopanib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000536	0.00305	CcSEcCtD
Pazopanib—PDGFRA—nervous system—amyotrophic lateral sclerosis	0.000536	0.00329	CbGeAlD
Pazopanib—EPHB6—cerebellum—amyotrophic lateral sclerosis	0.000532	0.00326	CbGeAlD
Pazopanib—MAP3K2—brain—amyotrophic lateral sclerosis	0.00053	0.00325	CbGeAlD
Pazopanib—STK10—central nervous system—amyotrophic lateral sclerosis	0.000521	0.0032	CbGeAlD
Pazopanib—TAOK3—central nervous system—amyotrophic lateral sclerosis	0.000519	0.00318	CbGeAlD
Pazopanib—PDGFRA—central nervous system—amyotrophic lateral sclerosis	0.000516	0.00316	CbGeAlD
Pazopanib—STK10—cerebellum—amyotrophic lateral sclerosis	0.000509	0.00312	CbGeAlD
Pazopanib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000508	0.0029	CcSEcCtD
Pazopanib—KIT—spinal cord—amyotrophic lateral sclerosis	0.000508	0.00312	CbGeAlD
Pazopanib—TAOK3—cerebellum—amyotrophic lateral sclerosis	0.000507	0.00311	CbGeAlD
Pazopanib—PDGFRA—cerebellum—amyotrophic lateral sclerosis	0.000504	0.00309	CbGeAlD
Pazopanib—FGF1—brain—amyotrophic lateral sclerosis	0.000499	0.00306	CbGeAlD
Pazopanib—PDGFRB—spinal cord—amyotrophic lateral sclerosis	0.000496	0.00304	CbGeAlD
Pazopanib—KDR—nervous system—amyotrophic lateral sclerosis	0.000483	0.00296	CbGeAlD
Pazopanib—MAP2K5—nervous system—amyotrophic lateral sclerosis	0.000483	0.00296	CbGeAlD
Pazopanib—CSF1R—nervous system—amyotrophic lateral sclerosis	0.000472	0.00289	CbGeAlD
Pazopanib—FGFR2—brain—amyotrophic lateral sclerosis	0.000471	0.00289	CbGeAlD
Pazopanib—KDR—central nervous system—amyotrophic lateral sclerosis	0.000465	0.00285	CbGeAlD
Pazopanib—MAP2K5—central nervous system—amyotrophic lateral sclerosis	0.000465	0.00285	CbGeAlD
Pazopanib—KDR—cerebellum—amyotrophic lateral sclerosis	0.000455	0.00279	CbGeAlD
Pazopanib—MAP2K5—cerebellum—amyotrophic lateral sclerosis	0.000455	0.00279	CbGeAlD
Pazopanib—CSF1R—central nervous system—amyotrophic lateral sclerosis	0.000454	0.00278	CbGeAlD
Pazopanib—CSF1R—cerebellum—amyotrophic lateral sclerosis	0.000444	0.00272	CbGeAlD
Pazopanib—FLT1—brain—amyotrophic lateral sclerosis	0.000437	0.00268	CbGeAlD
Pazopanib—EPHB6—brain—amyotrophic lateral sclerosis	0.000432	0.00265	CbGeAlD
Pazopanib—KIT—nervous system—amyotrophic lateral sclerosis	0.000428	0.00263	CbGeAlD
Pazopanib—PDGFRB—nervous system—amyotrophic lateral sclerosis	0.000418	0.00257	CbGeAlD
Pazopanib—STK10—brain—amyotrophic lateral sclerosis	0.000414	0.00254	CbGeAlD
Pazopanib—KIT—central nervous system—amyotrophic lateral sclerosis	0.000412	0.00253	CbGeAlD
Pazopanib—TAOK3—brain—amyotrophic lateral sclerosis	0.000412	0.00253	CbGeAlD
Pazopanib—PDGFRA—brain—amyotrophic lateral sclerosis	0.000409	0.00251	CbGeAlD
Pazopanib—KIT—cerebellum—amyotrophic lateral sclerosis	0.000403	0.00247	CbGeAlD
Pazopanib—PDGFRB—central nervous system—amyotrophic lateral sclerosis	0.000403	0.00247	CbGeAlD
Pazopanib—PDGFRB—cerebellum—amyotrophic lateral sclerosis	0.000394	0.00241	CbGeAlD
Pazopanib—KDR—brain—amyotrophic lateral sclerosis	0.000369	0.00227	CbGeAlD
Pazopanib—MAP2K5—brain—amyotrophic lateral sclerosis	0.000369	0.00227	CbGeAlD
Pazopanib—CSF1R—brain—amyotrophic lateral sclerosis	0.00036	0.00221	CbGeAlD
Pazopanib—KIT—brain—amyotrophic lateral sclerosis	0.000327	0.00201	CbGeAlD
Pazopanib—PDGFRB—brain—amyotrophic lateral sclerosis	0.00032	0.00196	CbGeAlD
Pazopanib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000313	0.00192	CbGeAlD
Pazopanib—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000308	0.00189	CbGeAlD
Pazopanib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000279	0.00171	CbGeAlD
Pazopanib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000241	0.00148	CbGeAlD
Pazopanib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000221	0.00136	CbGeAlD
Pazopanib—CYP2C8—brain—amyotrophic lateral sclerosis	0.000185	0.00113	CbGeAlD
Pazopanib—ABCG2—brain—amyotrophic lateral sclerosis	0.00018	0.0011	CbGeAlD
Pazopanib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000164	0.001	CbGeAlD
Pazopanib—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000161	0.000988	CbGeAlD
Pazopanib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000158	0.000967	CbGeAlD
Pazopanib—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000155	0.000952	CbGeAlD
Pazopanib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000154	0.000946	CbGeAlD
Pazopanib—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000152	0.00093	CbGeAlD
Pazopanib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000138	0.000844	CbGeAlD
Pazopanib—CYP2D6—brain—amyotrophic lateral sclerosis	0.000123	0.000755	CbGeAlD
Pazopanib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000116	0.000711	CbGeAlD
Pazopanib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000112	0.000685	CbGeAlD
Pazopanib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000109	0.000669	CbGeAlD
Pazopanib—ABCB1—brain—amyotrophic lateral sclerosis	8.86e-05	0.000543	CbGeAlD
Pazopanib—BMPR1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.9e-05	9.47e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.89e-05	9.43e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—SQSTM1—amyotrophic lateral sclerosis	1.88e-05	9.38e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CD40LG—amyotrophic lateral sclerosis	1.88e-05	9.35e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CD40LG—amyotrophic lateral sclerosis	1.87e-05	9.33e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—APOE—amyotrophic lateral sclerosis	1.85e-05	9.21e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—ERBB4—amyotrophic lateral sclerosis	1.84e-05	9.18e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—ERBB4—amyotrophic lateral sclerosis	1.84e-05	9.16e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	1.82e-05	9.07e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.81e-05	9.04e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.81e-05	9.02e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.8e-05	8.99e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.8e-05	8.97e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.8e-05	8.95e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—ERBB4—amyotrophic lateral sclerosis	1.79e-05	8.94e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.79e-05	8.93e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—C3—amyotrophic lateral sclerosis	1.78e-05	8.87e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.78e-05	8.86e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.77e-05	8.83e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—ATF1—amyotrophic lateral sclerosis	1.77e-05	8.8e-05	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.76e-05	8.76e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—ERBB4—amyotrophic lateral sclerosis	1.76e-05	8.75e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.75e-05	8.74e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.75e-05	8.74e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—C3—amyotrophic lateral sclerosis	1.75e-05	8.71e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.74e-05	8.66e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	1.71e-05	8.5e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.7e-05	8.46e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.69e-05	8.43e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.69e-05	8.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD40LG—amyotrophic lateral sclerosis	1.69e-05	8.4e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.68e-05	8.39e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.68e-05	8.39e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CASP9—amyotrophic lateral sclerosis	1.68e-05	8.38e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	1.68e-05	8.37e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.67e-05	8.34e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.67e-05	8.33e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.67e-05	8.31e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.66e-05	8.28e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—C3—amyotrophic lateral sclerosis	1.66e-05	8.26e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—ERBB4—amyotrophic lateral sclerosis	1.66e-05	8.25e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—C3—amyotrophic lateral sclerosis	1.65e-05	8.24e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD40LG—amyotrophic lateral sclerosis	1.65e-05	8.23e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.65e-05	8.22e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.65e-05	8.2e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.65e-05	8.2e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.64e-05	8.18e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.62e-05	8.07e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.62e-05	8.06e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.61e-05	8.04e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.59e-05	7.92e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.59e-05	7.91e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.58e-05	7.89e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.58e-05	7.87e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.57e-05	7.84e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.56e-05	7.76e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CASP9—amyotrophic lateral sclerosis	1.55e-05	7.74e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	1.55e-05	7.73e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	1.54e-05	7.68e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.54e-05	7.68e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—APOE—amyotrophic lateral sclerosis	1.53e-05	7.62e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—PTGS2—amyotrophic lateral sclerosis	1.52e-05	7.59e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.52e-05	7.56e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.51e-05	7.51e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.51e-05	7.5e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.5e-05	7.49e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—APOE—amyotrophic lateral sclerosis	1.5e-05	7.48e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.5e-05	7.45e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—C3—amyotrophic lateral sclerosis	1.49e-05	7.43e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.49e-05	7.4e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.48e-05	7.35e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.46e-05	7.3e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—C3—amyotrophic lateral sclerosis	1.46e-05	7.27e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.46e-05	7.26e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—ERBB4—amyotrophic lateral sclerosis	1.44e-05	7.17e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—APOE—amyotrophic lateral sclerosis	1.43e-05	7.1e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.43e-05	7.1e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.42e-05	7.09e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—APOE—amyotrophic lateral sclerosis	1.42e-05	7.08e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.41e-05	7.04e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.4e-05	6.98e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.4e-05	6.97e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.39e-05	6.94e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.39e-05	6.94e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.39e-05	6.93e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.39e-05	6.91e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.38e-05	6.9e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.38e-05	6.87e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.36e-05	6.78e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.36e-05	6.76e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.35e-05	6.75e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD40LG—amyotrophic lateral sclerosis	1.35e-05	6.74e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.35e-05	6.73e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—ERBB4—amyotrophic lateral sclerosis	1.33e-05	6.62e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.33e-05	6.61e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.32e-05	6.56e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.31e-05	6.52e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.3e-05	6.49e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.3e-05	6.48e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.3e-05	6.46e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.29e-05	6.45e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.29e-05	6.43e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.29e-05	6.41e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.29e-05	6.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—APOE—amyotrophic lateral sclerosis	1.28e-05	6.38e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.28e-05	6.37e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.27e-05	6.35e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.27e-05	6.34e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—PTGS2—amyotrophic lateral sclerosis	1.27e-05	6.31e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.23e-05	6.11e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.22e-05	6.07e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.22e-05	6.06e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.21e-05	6.05e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.21e-05	6.03e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—C3—amyotrophic lateral sclerosis	1.2e-05	5.96e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.19e-05	5.95e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.19e-05	5.94e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.19e-05	5.93e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.17e-05	5.82e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.16e-05	5.79e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.16e-05	5.78e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.15e-05	5.73e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.15e-05	5.73e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.15e-05	5.71e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.14e-05	5.69e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.14e-05	5.66e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.13e-05	5.63e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.12e-05	5.59e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.11e-05	5.55e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.11e-05	5.53e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.1e-05	5.5e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.1e-05	5.48e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.09e-05	5.45e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.09e-05	5.43e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.09e-05	5.42e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.08e-05	5.37e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.07e-05	5.34e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.07e-05	5.34e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.07e-05	5.33e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.07e-05	5.33e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.07e-05	5.32e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—amyotrophic lateral sclerosis	1.06e-05	5.26e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.05e-05	5.24e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PTGS2—amyotrophic lateral sclerosis	1.05e-05	5.22e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.05e-05	5.21e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PTGS2—amyotrophic lateral sclerosis	1.03e-05	5.13e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—APOE—amyotrophic lateral sclerosis	1.03e-05	5.12e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.01e-05	5.05e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.98e-06	4.97e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.96e-06	4.96e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.91e-06	4.94e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	9.89e-06	4.93e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—APOE—amyotrophic lateral sclerosis	9.83e-06	4.9e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	9.82e-06	4.89e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PTGS2—amyotrophic lateral sclerosis	9.77e-06	4.87e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PTGS2—amyotrophic lateral sclerosis	9.74e-06	4.85e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.64e-06	4.8e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.43e-06	4.7e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.36e-06	4.66e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	9.31e-06	4.64e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	9.02e-06	4.49e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—APOE—amyotrophic lateral sclerosis	9.01e-06	4.49e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.97e-06	4.47e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	8.86e-06	4.41e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.85e-06	4.41e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.85e-06	4.41e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.78e-06	4.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PTGS2—amyotrophic lateral sclerosis	8.78e-06	4.37e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.75e-06	4.36e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.69e-06	4.33e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—amyotrophic lateral sclerosis	8.66e-06	4.31e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.63e-06	4.3e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.41e-06	4.19e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.37e-06	4.17e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	8.34e-06	4.16e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	8.33e-06	4.15e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.32e-06	4.14e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.25e-06	4.11e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.23e-06	4.1e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.23e-06	4.1e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.15e-06	4.06e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	8.08e-06	4.03e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.96e-06	3.97e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.78e-06	3.88e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.73e-06	3.85e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.51e-06	3.74e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.41e-06	3.69e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.32e-06	3.65e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.26e-06	3.62e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.2e-06	3.59e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTGS2—amyotrophic lateral sclerosis	7.04e-06	3.51e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.99e-06	3.48e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.85e-06	3.41e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	6.84e-06	3.41e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.81e-06	3.39e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.74e-06	3.36e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.69e-06	3.33e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.44e-06	3.21e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.35e-06	3.16e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.35e-06	3.16e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.33e-06	3.16e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.32e-06	3.15e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.29e-06	3.13e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.17e-06	3.08e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6e-06	2.99e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.99e-06	2.98e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.96e-06	2.97e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.95e-06	2.96e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.78e-06	2.88e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.72e-06	2.85e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.71e-06	2.84e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.68e-06	2.83e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.68e-06	2.83e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.62e-06	2.8e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.59e-06	2.78e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.54e-06	2.76e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.53e-06	2.76e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.48e-06	2.73e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.39e-06	2.69e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.39e-06	2.68e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.37e-06	2.68e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.28e-06	2.63e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.28e-06	2.63e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	5.18e-06	2.58e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.16e-06	2.57e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.84e-06	2.41e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.76e-06	2.37e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.74e-06	2.36e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.58e-06	2.28e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	4.51e-06	2.25e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.38e-06	2.18e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.37e-06	2.18e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.33e-06	2.16e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.29e-06	2.14e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	4.25e-06	2.12e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.07e-06	2.03e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.06e-06	2.02e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.89e-06	1.94e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.67e-06	1.83e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.66e-06	1.82e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	3.6e-06	1.79e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.58e-06	1.78e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.55e-06	1.77e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.38e-06	1.68e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.09e-06	1.54e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.94e-06	1.46e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.91e-06	1.45e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2.78e-06	1.38e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.47e-06	1.23e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.9e-06	9.48e-06	CbGpPWpGaD
